EUCTR2020-005016-21-ES进行中（未招募）1 期
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in combination with nivolumab in adults with advanced solid tumours
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 74
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Previously treated subjects with recurrent and metastatic NSCLC, pancreatic cancer, ovarian cancer, papillary thyroid cancer, colorectal adenocarcinoma and melanoma with documented progression/intolerance following at least one previous therapy (and not more than 2 previous regimens).
- •2. Adequate safety lab results at Screening and at Baseline (Day 1) for those tests that require repeating at Baseline, including the following:
- •a. Albumin =3 g/dL;
- •b. Bilirubin =1.5 times the upper limit of normal (ULN) or <3 times the ULN in the case of Gilbert Syndrome;
- •c. Aspartate aminotransaminase (AST), alanine aminotransaminase (ALT), and alkaline phosphatase =3 times the ULN;
- •d. Serum creatinine =1.5xULN and creatinine clearance >40 mL/minute based on the Cockcroft-Gault equation [creatinine clearance in mL/min = (140 – age in years) x body weight (kg)/72 x serum creatinine (mg/dL); multiplied by 0.85 for women];
- •e. White blood cell (WBC) count =2000/uL; neutrophils =1500/uL; hemoglobin =9 g/dL; platelets =100x103/uL.
- •3. Brain metastases should be stable following radiosurgery with at least 4 weeks since the end of definitive therapy (i.e., radiotherapy) and without need for steroid therapy as evidenced by imaging performed after completion of any CNS directed therapy demonstrating radiographic stability of CNS lesions.
- •4. Must have at least 1 measurable lesion per RECIST1.1 with progressing or new tumors since last antitumor therapy.
- •5. Age =18 years at the time of signing ICF;
- •1. Subjects with histologically confirmed metastatic or locally advanced non-small cell lung cancer (NSCLC) with documented progression following anti-PD-1/PD-L1 containing therapy; Subjects must have confirmation of progression of disease that is consistent with iCPD during or within 3 months of prior anti-PD1/PDL1 with either two radiographic scans showing disease progression or documented clinical progression (e.g., worsening of symptoms).
- •2. Subjects could have had a maximum of 1 prior treatment regimen.
- •3. Adequate safety lab results at Screening and at Baseline (Day 1) for those tests that require repeating at Baseline, including the following:
- •a. Albumin =3 g/dL;
- •b. Bilirubin =1.5 times the upper limit of normal (ULN) or <3 times the ULN in the case of Gilbert Syndrome;
- •c. Aspartate aminotransaminase (AST), alanine aminotransaminase (ALT), and alkaline phosphatase =3 times the ULN;
- •d. Serum creatinine =1.5xULN and Creatinine clearance >40 mL/minute based on the Cockcroft-Gault equation [creatinine clearance in mL/min = (140 – age in years) x body weight (kg)/72 x serum creatinine (mg/dL); multiplied by 0.85 for women];
- •e. White blood cell (WBC) count =2000/uL; neutrophils =1500/uL; hemoglobin =9 g/dL; platelets =100x103/uL.
- •4. Brain metastases should be stable following radiosurgery with at least 4 weeks since the end of definitive therapy (i.e., radiotherapy) and without need for steroid therapy as evidenced by imaging performed after completion of any CNS directed therapy demonstrating radiographic stability of CNS lesions.
- •5. Must have at least 1 measurable lesion per RECIST1.1 with progressing or new tumors since last antitumor therapy.
- •1. Subjects with histologically confirmed metastatic pancreatic adenocarcinoma as defined by NCCN Guidelines; Subjects with islet cell neoplasms are excluded.
- •2. Subjects with a maximum of 1 prior treatment regimen for metastatic disease excluding nab-paclitaxel containing regimens and up to 8 weeks fro
排除标准
- •1. History of weight loss >10% over the 2 months prior to Screening.
- •2. Received more than two prior systemic regimens for the metastatic disease.
- •3. Unresolved AEs > Grade 1 from prior anticancer therapy. Exempted are effects that are often non-reversible or require a prolonged time for reversal (e.g., alopecia, hypothyroidism, neuropathy).
- •4. Concurrent malignancy requiring treatment. Participants with a previously treated malignancy are eligible if treatment was completed at least 2 years before study start and the patient has no evidence of disease. Participants who have a concurrent malignancy that is clinically stable and does not require tumor-directed treatment or with a history of prior early stage basal/squamous cell skin cancer or non-invasive or in situ cancers that have undergone definitive treatment at any time are also eligible.
- •5. Active, untreated central nervous system (CNS) metastases.
- •6. Subjects previously treated with an anti PD-1/PD-L1 targeting agent with history immune mediated toxicity of = Grade 3, treatment of their toxicity with systemic corticosteroids, or any hypersensitivity to PD-1/PDL-1 targeting agents or any other antibody or drug specifically targeting T cell co-stimulation or immune checkpoint pathways.
- •7. Severely immunocompromised as defined by white blood cell (WBC) count <2000/mm3 and/or CD4+ lymphocyte count =200/mm3.
- •8. History of allergy or hypersensitivity to any of the study treatment components
- •9. Major surgery within 4 weeks of study administration.
- •10. Participants who have received a live / attenuated vaccine within 30 days of first treatment;
- •11. Subjects with serious or uncontrolled medical disorders other than the metastatic disease;
- •12. Any condition which, in the opinion of the PI, places the subject at unacceptable risk if he/she were to participate in the study.
- •Parts B and C
- •1. History of weight loss >10% over the 2 months prior to Screening;
- •2. Received more than 1 prior systemic regimens for the advanced/recurrent and/or metastatic disease;
- •3. Unresolved AEs > Grade 1 from prior anticancer therapy. Exempted are effects that are often non-reversible or require a prolonged time for reversal (e.g., alopecia, hypothyroidism, neuropathy).
- •4. Concurrent malignancy requiring treatment. Participants with a previously treated malignancy are eligible if treatment was completed at least 2 years before study start and the patient has no evidence of disease. Participants who have a concurrent malignancy that is clinically stable and does not require tumor-directed treatment or with a history of prior early stage basal/squamous cell skin cancer or non-invasive or in situ cancers that have undergone definitive treatment at any time are also eligible.
- •5. Active and/or untreated central nervous system (CNS) metastases including leptomeningeal metastases;
- •6. Severely immunocompromised as defined by white blood cell (WBC) count <2000/mm3 and/or CD4+ lymphocyte count =200/mm3.
- •7. History of allergy or hypersensitivity to any of the study treatment components; subjects previously treated with an anti PD-1/PD-L1 targeting agent with history of immune-mediated toxicity of = Grade 3 treatment of their toxicity with systemic corticosteroids, or any hypersensitivity to PD-1/PD-L1 targeting agents or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways.
- •8. Major surgery within 4 weeks of study administration;
- •9. Participants who have received a l
研究者
相似试验
进行中（未招募）
不适用
A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women with Breast Cancer and Established Bone Metastases (MBD) - Women with Breast Cancer and Established Metastatic Bone DiseaseMetastaic Bone Disease (MBD)MedDRA version: 8.1Level: LLTClassification code 10027452Term: Metastases to boneEUCTR2006-002669-38-DKMerck & Co., Inc.
进行中（未招募）
不适用
A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women with Breast Cancer and Established Bone Metastases (MBD) - Women with Breast Cancer and Established Metastatic Bone DiseaseMetastatic Bone Disease (MBD)MedDRA version: 8.1Level: LLTClassification code 10027452Term: Metastases to boneEUCTR2006-002669-38-DEMerck & Co Inc.45
进行中（未招募）
1 期
A Phase II Study to Assess the Safety, Tolerability, and Efficacy of MK-0822 (Cathepsin-K Inhibitor) in the Treatment of Women with Breast Cancer and Established Bone Metastases (MBD) - Women with Breast Cancer and Established Metastatic Bone DiseaseMetastaic Bone Disease (MBD)MedDRA version: 8.1 Level: LLT Classification code 10027452 Term: Metastases to boneEUCTR2006-002669-38-NOMSD (Norge) AS56
招募中
1 期
A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR -2218, VIR-3434, and/or PEG-IFNa in Subjects with Chronic Hepatitis B Virus InfectioEUCTR2021-001033-39-DEVir Biotechnology, Inc.260
进行中（未招募）
1 期
A Phase 1/2 Study of AMG 193 in Combination with IDE397 in Subjects with Advanced MTAP-null Solid TumorsCTIS2023-504364-42-00Amgen Inc.184